INDV — Indivior Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$37.93
Market Cap
$4.48B
52W High
$41.00
52W Low
$27.68
ADV30
1,804,813
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 317,000,000 | 277,000,000 | 137,000,000 | 89,000,000 | 1,197,000,000 | 175,000,000 | 1,341,000,000 |
| Dec 2025 | 358,000,000 | 291,000,000 | 83,000,000 | 102,000,000 | 1,201,000,000 | 195,000,000 | 1,300,000,000 |
| Sep 2025 | 314,000,000 | 231,000,000 | 44,000,000 | 42,000,000 | 1,416,000,000 | 445,000,000 | 1,623,000,000 |
| Jun 2025 | 302,000,000 | 250,000,000 | 71,000,000 | 18,000,000 | 1,452,000,000 | 510,000,000 | 1,710,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-267,000,000
Investing CF
$-29,000,000
Financing CF
$-52,000,000
CapEx
$-82,000,000
Dividends Paid
—
Buybacks
$-126,000,000
EPS Diluted TTM
$2.19
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-280,000,000
Inventory
$152,000,000
Receivables
$285,000,000
ST Investments
—
EBIT TTM
$335,000,000
Pretax Income TTM
$295,000,000
Interest Exp TTM
$40,000,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,290,000,000
EBITDA
$475,000,000
Free Cash Flow
$44,250,000
Enterprise Value
$4,968,257,536
Total Cash
$175,000,000
Total Debt
$509,000,000
Shares Out
118,204,585
Trailing EPS
$1.95
Book Value
$-1.18
ROE
—
ROA
22.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,239,000,000 | 265,000,000 | 210,000,000 | 1,201,000,000 | 1,300,000,000 | — | -27,000,000 |
| Dec 2024 | 1,188,000,000 | 234,000,000 | 7,000,000 | 1,316,000,000 | 1,653,000,000 | — | 36,000,000 |
| Dec 2023 | 1,093,000,000 | 247,000,000 | -126,000,000 | 1,760,000,000 | 1,952,000,000 | — | -300,000,000 |
| Dec 2022 | 901,000,000 | 215,000,000 | -44,000,000 | 1,769,000,000 | 1,718,000,000 | — | -4,000,000 |
TTM Snapshot
Revenues TTM
$299,000,000
NetIncome TTM
$-97,000,000
OpCashFlow TTM
$0
Assets (Latest)
$1,758,000,000
Forward EPS
$3.92
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $37.93 · call volume: 50 · put volume: 42
Expected Move to 2026-12-18:
±$14.50
(38.23%) —
implied range
$23.43 –
$52.43
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.48B | $81.89 | — |
| GIFLF | Grifols SA | $4.41B | $10.45 | — |
| ERAS | Erasca, Inc. | $4.35B | $13.98 | — |
| ORKA | Oruka Therapeutics, Inc. | $4.27B | $70.88 | — |
| GIKLY | Grifols SA | $4.81B | $5.69 | — |
News headlines (Yahoo Finance, 1h cache)
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
2026-06-17 15:11 · Yahoo
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
2026-06-17 14:29 · Yahoo
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
2026-06-17 14:20 · Yahoo
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
2026-06-16 14:13 · Yahoo
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
2026-06-16 12:47 · Yahoo
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan
2026-06-15 21:14 · Yahoo
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
2026-06-15 16:12 · Yahoo
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?
2026-06-13 13:54 · Yahoo
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
2026-06-12 14:20 · Yahoo
Is Indivior Stock a Buy After Higher 2026 Guidance?
2026-06-12 14:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.